Vitamin D3 for Life

Live Enlightened

Article

Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data: Full Evidence Review

Previous related pageVitamin D Status, Spirometry and Asthma in UK Biobank: Study SummaryNext related pageVitamin D, Mucosal Surveillance and Local Gut and Airway Defence: Full Evidence Review
Study at a glance

Can vitamin D supplements help prevent respiratory infections?

Researchers combined records for individual people from trials of vitamin D supplements. They asked whether supplements reduced the chance of having at least one respiratory infection, affecting the airways. People had been assigned by chance to treatment groups. The trials included different ages, countries, starting vitamin D levels and supplement schedules.

Who had the greatest reduction in infections with vitamin D?

The combined results showed a statistically clear reduction in infection risk with vitamin D supplements. The reduction was larger among people whose vitamin D levels were lower before treatment. Daily or weekly schedules showed more consistent reductions than large doses given less often. Some groups showed little or no apparent benefit, especially those starting with higher vitamin D levels.

Why are the vitamin D infection trials difficult to compare?

Trials recorded infections differently: some used people’s reports of symptoms, while others used medical diagnoses. Some information from before treatment was missing. The analysis did not establish effects against particular causes of infection or identify the exact changes in the immune system.

Do these results show that vitamin D can treat an existing infection?

The findings concern prevention of respiratory infections, mainly among people living in the community. They do not show that vitamin D protects everyone or treats an infection that has already started. They also do not establish benefits for other immune conditions or provide a personal supplement schedule.

Read the full article below ↓

Evidence from a single verified study evaluated using a fixed, auditable study-page structure.

Study classification and identity

Study type
Systematic review and individual participant data meta-analysis of randomised, double-blind, placebo-controlled trials

Parent study
Not applicable

Ancillary study focus
Not applicable

Exposure type
Vitamin D exposure delivered via supplementation across heterogeneous dosing schedules

Intervention arms or exposure groups
Vitamin D versus placebo or no supplementation, including daily, weekly, and intermittent bolus regimens

Primary endpoint category
Incidence of acute respiratory tract infection

Clinical endpoints assessed
Occurrence of one or more acute respiratory tract infections during prospective follow-up

Study purpose and framing

This study was undertaken to address long-standing uncertainty regarding whether vitamin D supplementation influences susceptibility to acute respiratory tract infections when evaluated across diverse populations and settings. Rather than approaching the question from a treatment or therapeutic angle, the authors framed the investigation around immune robustness, defined as the capacity of the host immune system to resist infection across repeated environmental exposures. This framing intentionally positions infection incidence as a functional outcome of immune regulation rather than as a proxy for downstream clinical management.

A central motivation for the work was the inconsistency of findings reported in earlier aggregate-level meta-analyses, which had analysed many of the same trials yet reached conflicting conclusions. The authors recognised that immune resilience is shaped by baseline physiological context, exposure frequency, and temporal dynamics, all of which may be masked when participant-level variability is collapsed into summary statistics. The study therefore set out to examine these relationships at a finer analytical resolution.

By adopting an individual participant data approach, the authors sought to disentangle whether apparent inconsistencies reflected true biological heterogeneity or methodological artefacts. This framing acknowledges immune function as an adaptive, distributed system whose performance emerges over time, rather than as a binary outcome that can be inferred from a single measurement or averaged effect size.

The study purpose is thus explicitly preventative and system-oriented. Infection prevention is treated as an emergent property of coordinated immune activity operating across repeated challenges, rather than as evidence of direct modulation of any single immune pathway.

Why the primary measure is used as a biological marker

Incidence of acute respiratory tract infection was selected as the primary biological marker because it reflects the integrated performance of immune defences under real-world conditions. Preventing infection requires the coordinated action of barrier integrity, innate immune recognition, adaptive immune priming, and effective resolution, making infection occurrence a functional readout of immune competence over time.

Unlike isolated laboratory measures captured at a single time point, infection incidence accumulates information across multiple exposures and environmental contexts. From the perspective of immune resilience, this cumulative property is particularly relevant, as it reflects the system’s capacity to maintain stability in the face of repeated perturbations rather than its response to an isolated challenge.

The authors explicitly acknowledged that infection outcomes are influenced by exposure intensity, reporting practices, and access to healthcare. However, the use of individual participant data allowed these sources of variability to be examined and adjusted for rather than treated as unstructured noise, strengthening the interpretive value of the marker.

While the measure does not identify specific molecular mechanisms, it provides a biologically meaningful functional endpoint aligned with the study’s framing of immune robustness and resistance to dysregulation under routine infectious stress.

Study overview

The analysis incorporated individual-level data from a large number of randomised controlled trials conducted across multiple countries, age groups, and seasonal contexts. Participants were primarily community-dwelling individuals exposed to routine respiratory pathogens, with substantial variation in baseline vitamin D status and infection risk.

Each contributing trial followed participants prospectively, recording respiratory infection outcomes over defined follow-up periods. The individual datasets were pooled while preserving original randomisation, allowing the authors to assess both overall effects and context-dependent variation.

The scale of the combined dataset enabled examination of effect modification by baseline status, dosing pattern, and demographic factors. This analytical breadth distinguishes the study from earlier analyses that were limited by smaller sample sizes or aggregated reporting.

The overview therefore reflects both the breadth of the underlying evidence base and the study’s aim to characterise immune resilience as a heterogeneous phenomenon shaped by individual and contextual factors.

Study design and measurement approach

Individual participant data were obtained directly from trial investigators and subjected to a harmonisation process to align outcome definitions, inclusion criteria, and covariate coding. This step was critical for ensuring comparability across trials that had been independently designed and implemented.

The authors conducted extensive data quality checks to identify missing values, inconsistencies, and protocol deviations. Sensitivity analyses were used to evaluate the robustness of findings to these issues, reflecting a cautious and transparent analytical approach.

Incorporating heterogeneous trial designs required explicit modelling of trial-level effects. Rather than attempting to eliminate heterogeneity, the analytical strategy treated it as an informative feature that could reveal context-dependent differences in immune response.

Despite rigorous harmonisation, methodological constraints remained, including variation in infection ascertainment methods and supplementation protocols. These constraints were explicitly acknowledged and incorporated into the analytical framework.

Outcome hierarchy

Directly measured
Occurrence of acute respiratory tract infection during follow-up

Not measured
Immune cell phenotypes, cytokine profiles, or intracellular signalling activity

Not inferable from this study
Specific molecular mechanisms linking vitamin D signalling to pathogen defence

Statistical analysis

Primary analyses employed mixed-effects regression models that accounted for clustering of participants within trials. This approach preserved the integrity of within-trial randomisation while enabling incorporation of individual-level covariates across the pooled dataset.

Baseline vitamin D status, age, and dosing frequency were included as covariates, with prespecified interaction terms used to examine effect modification. This strategy allowed the authors to explore heterogeneity without resorting to post hoc subgroup analyses.

The use of individual participant data also enabled consistent handling of missing data and outcome definitions across trials, improving inferential reliability relative to aggregate meta-analytic methods.

Results

Across the pooled population, vitamin D supplementation was associated with a statistically significant reduction in the risk of experiencing at least one acute respiratory tract infection. This association remained after adjustment for individual-level covariates and trial-level heterogeneity, indicating that the observed effect was not driven solely by a small subset of studies.

Stratified analyses revealed that baseline vitamin D status was an important modifier of effect. Individuals with lower baseline status experienced the most pronounced reductions in infection risk, suggesting that immune robustness under repeated infectious stress may be particularly sensitive to underlying physiological context.

Dosing pattern also influenced outcomes. Regular daily or weekly supplementation was associated with more consistent reductions in infection incidence compared with infrequent high-dose bolus regimens. This temporal patterning highlights the potential relevance of exposure stability to immune regulation, without implying specific mechanistic pathways.

Substantial between-individual variability was observed, with some participants deriving minimal or no apparent benefit. This heterogeneity reinforces the authors’ interpretation of immune resilience as a distributed and context-dependent property rather than a uniform response.

Importantly, the analysis also identified instances of null or attenuated effects, particularly in subgroups with higher baseline vitamin D status. These findings underscore that supplementation did not confer universal protection and that its association with infection risk is conditional rather than absolute.

Measurement considerations and limitations

Respiratory infection outcomes were derived from a mix of self-reported symptoms and clinician diagnoses, depending on trial protocol. This introduces potential misclassification, although the large sample size and harmonised analysis mitigate the influence of any single source of error.

The study did not differentiate between specific respiratory pathogens, limiting attribution of effects to particular immune defence mechanisms. Seasonal and environmental exposure variability may also contribute residual confounding.

Not all trials provided complete baseline data for all covariates, necessitating assumptions in model specification. These limitations were transparently reported and explored through sensitivity analyses.

Despite these constraints, the individual participant data approach represents a methodological advance over aggregate analyses and offers a more nuanced understanding of variability and context dependence.

Generalisability and population context

The findings are most applicable to community-dwelling populations exposed to routine seasonal respiratory infections. Extrapolation to hospitalised or severely immunocompromised populations should be undertaken cautiously.

The results should be interpreted specifically in relation to respiratory infection susceptibility and not generalised to unrelated immune outcomes.

Mechanistic inference boundary

This study supports an association between vitamin D exposure and functional immune robustness as reflected by infection incidence.

It does not identify or confirm specific molecular or cellular mechanisms underlying this association.

Interpretation within vitamin D physiology

Within the framework of vitamin D physiology, these findings are consistent with a role for vitamin D signalling in supporting immune resilience under repeated environmental stressors, particularly among individuals with lower baseline status.

The observed heterogeneity aligns with existing understanding that vitamin D acts within broader regulatory networks rather than as an isolated immune effector.

For relevant physiology background, see Vitamin D and Immune Resilience.

Interpretation

This study provides evidence that vitamin D supplementation is associated with reduced susceptibility to acute respiratory infections at the population level.

The findings emphasise conditional and context-dependent effects rather than universal immune enhancement.

Interpretation remains bounded to prevention outcomes and does not imply mechanistic certainty.

Primary source and publication details

Martineau AR, Jolliffe DA, Hooper RL, et al.

Vitamin D supplementation to prevent acute respiratory tract infections: systematic review and meta-analysis of individual participant data

BMJ. 2017.

DOI: Not applicable

https://pubmed.ncbi.nlm.nih.gov/28202713/

Related reading

Original sources